---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-25-000013"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T17:21:14.175565+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M

## Summary
- Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).
- Q4 adjusted gross margin 70% (vs 56% YoY); exome/genome margin >70%.
- Q4 adjusted net income $16.8M (GAAP net income $5.4M); full year adjusted net income $6.7M.
- FY2025 guidance: revenue $350M-$360M, exome/genome volume and revenue growth at least 30%.
- Cash $142.2M at year-end; Q4 operating cash flow $12.4M including $6.8M appeal recovery.

## SEC filing metadata
- accession: 0001818331-25-000013
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000013/0001818331-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000013/wgs-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-25-000013
- JSON: https://secwatch.observer/filing/0001818331-25-000013.json
- Plain text: https://secwatch.observer/filing/0001818331-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.